Wockhardt: R&D picks momentum - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Wockhardt: R&D picks momentum

Apr 2, 2002

Yesterday Wockhardt announced that the first molecule (WCK-771) from its research pipeline has entered in to Phase-I of clinical trials in India. WCK-771 is an anti-infective molecule used in the treatment of sepsis. The company has already started exploring opportunities for out licensing the molecule. Wockhardt has earlier highlighted the molecule’s superior safety and efficacy over currently available drugs such as Vancomycin (Aventis Pharma) and Linezolid (Pharmacia). According to the company, globally there are only a few competing drugs, which are under clinical development for the above product. The prevailing market size for such a drug is in excess of US$ 1 bn. Considering that the molecule has just finished pre-clinical trials it would take another 6-9 months time to complete Phase I clinical trials.

The biotech research of Wockhardt has already yielded results with two biotech products already in place. A major forthcoming highlight from this division is the commencement of human recombinant insulin manufacturing capacity. Currently, there are only three other companies in the world to have the required expertise in this field. The domestic requirement of human insulin is currently met through imports.

Wockhardt is planning to launch this product by end 2003 with an aggressive pricing of 30-40% discount to the imported alternatives. We expect the company to launch the same in developed markets within 18-24 months of domestic launch, keeping in mind regulatory approvals. Considering strong competitive advantage, we expect the company to capture a considerable share of the domestic Rs 3 bn insulin market (global demand US$ 3.5 bn).

As far as other research projects are concerned, the company is also working on 9 other NDDS projects. Acceptance of WCK-771 for clinical trials marks a good beginning for the company in the area of NCE (New chemical entity) research. However, it would be still premature to expect milestone payments at this point of time. It should be understood that chances of Phase I molecule finally succeeding are low and any earnings visibility is far fetched at this point of time. At the current market price of Rs 408, the stock trades at 14.5x FY02 expected earnings.


Equitymaster requests your view! Post a comment on "Wockhardt: R&D picks momentum ". Click here!

  

More Views on News

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Sep 18, 2020 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WOCKHARDT WITH

MARKET STATS